Loading…
Employees: 3,415
Size Yabao Pharmaceutical (600351.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $711M, the 3031st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥6.85 on 6 Nov 2026.
Performance Over six months the shares fell 3.2%, against -6.4% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue fell 3.5% over the last twelve months (peer median +16.1%); the operating margin is 15.6% (peer median 11.5%).
Valuation It trades at 1.7× enterprise value to sales against a peer median of 3.3× (5th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 12.2 points above its cost of capital (6.8% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.19B | CN¥2.22B | CN¥2.67B | CN¥2.89B | CN¥2.70B |
| Revenue growth | — | -17% | -8% | +7% | — |
| Gross profit | CN¥1.25B | CN¥1.11B | CN¥1.31B | CN¥1.60B | CN¥1.43B |
| EBITDA | n/a | CN¥453M | CN¥424M | CN¥449M | CN¥335M |
| Net income | CN¥362M | CN¥320M | CN¥243M | CN¥200M | CN¥105M |
| Free cash flow | CN¥613M | CN¥529M | CN¥440M | CN¥398M | CN¥403M |
| Capital expenditure | CN¥33.9M | CN¥48.9M | CN¥34.7M | CN¥99.9M | CN¥62.2M |
| Total debt | CN¥3.80M | CN¥38.5M | CN¥95.7M | CN¥268M | CN¥450M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600351.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.4% | -8.2% | 7th highest of 21 |
| 6-month return | -3.2% | -6.4% | 9th highest of 21 |
| Distance from 52-week high | -8.1% | -29.4% | 2nd highest of 21 |
| Revenue growth (TTM) | -3.5% | +16.1% | 4th lowest of 17 |
| Operating margin | 15.6% | 11.5% | 7th highest of 16 |
| EV / Sales | 1.7× | 3.3× | 5th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -7.5% | 10.3% | least demanding of 8 |
| Growth delivered (Del g) | -2.8% | +10.1% | 2nd lowest of 8 |
| Hurdle (Req g minus delivered) | -4.6 pp | +2.5 pp | 3rd least demanding of 8 |
| ROIC minus cost of capital | +12.2 pp | +0.5 pp | 4th highest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Yabao Pharmaceutical 600351.SS | China | $711M | -3% | -3% | 16% | 1.7× | -7.5% | -2.8% |
| Hainan Haiyao 000566.SZ | China | $710M | -19% | -18% | -50% | 11.2× | n/a | n/a |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $716M | -24% | +5% | -30% | 8.7× | n/a | n/a |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $705M | -29% | -82% | n/a | 27.3× | 10.5% | -25.1% |
| Ardelyx ARDX | United States | $724M | -58% | +18% | -8% | 1.5× | n/a | n/a |
| Bliss GVS Pharma BLISSGVS.NS | India | $698M | +126% | +21% | 15% | 6.6× | 37.0% | +10.1% |
| Arbutus Biopharma ABUS | United States | $724M | -16% | +1,079% | 81% | 3.5× | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $725M | +4% | +26% | 61% | 2.7× | n/a | n/a |
| Cullinan Therapeutics CGEM | United States | $728M | -22% | n/a | n/a | n/a | n/a | n/a |
| Philogen PHIL.MI | Italy | $694M | -7% | +295% | 79% | 0.9× | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $693M | +28% | n/a | n/a | n/a | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $692M | -16% | +23% | 11% | 3.2× | 10.3% | +7.9% |
| Achieve Life Sciences ACHV | United States | $692M | +29% | n/a | n/a | n/a | n/a | n/a |
| Zevra Therapeutics ZVRA | United States | $690M | +4% | +75% | 31% | 3.4× | 0.0% | +51.6% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 2.5× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 10.9× | 41.4% | +11.2% |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 0.7× | n/a | n/a |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | n/a | n/a | n/a | n/a |
| Rigel Pharmaceuticals RIGL | United States | $741M | +52% | +3% | 31% | 2.5× | -1.1% | +22.1% |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $682M | -5% | +13% | 4% | 6.2× | n/a | n/a |
| Earth 4985.T | Japan | $682M | +6% | +6% | 4% | 0.6× | -2.5% | -1.8% |